Introducing MacuMira
Innovation in Dry AMD care
A non-invasive Microcurrent Stimulation for Dry AMD
Our MacuMira device empowers eyecare professionals with a safe, effective, and non-invasive treatment that delivers measurable vision improvements.
Register for more information or to book a demo!
Submit your details below:
The MacuMira solution
AMD is the leading cause of blindness in adults, affecting over 1.5 million Australians¹ and tens of thousands of New Zealanders².
The MacuMira device is the first and only TGA and Medsafe-listed microcurrent treatment for Dry AMD
Using non-invasive Microcurrent Stimulation, the device offers a breakthrough approach, designed to improve visual function and independence for patients.
Easy to administer, the device elevates patient care via a safe, and pain-free treatment that requires no injections or systemic drugs
How it works
- A loading phase of 4 x 32-minute sessions improves vision within days
- One maintenance treatment every 2–3 months sustains results
- Microcurrent Stimulation (MCS) stimulates the mitochondria, which boosts ATP production for healthier retinal cells
- Most patients start to see improvements within 10 days*
*Parkinson, K. M., Sayre, E. C., & Tobe, S. W. (2023). Evaulation of visual acuity in dry AMD patients after microcurrent electrical stimulation.
Int. Journal of Retina and Vitreous, 9, 36.
Introducing MacuMira
Watch this video to discover how MacuMira can elevate your patient care with innovative Dry AMD technology